Comparisons of mescal bean alkaloids with mescaline, Δ9 - THC and other psychotogens

Psilocybin, a hallucinogen, significantly reduced anxiety and depression symptoms in 70% of participants in a clinical trial involving 100 adults. This study explored the pharmacology of psychedelics, noting their influence on neurotransmitter receptors, which may alter behavior. Participants reported improved emotional well-being after treatment, comparable to traditional medicine approaches. The findings suggest that psychedelics like psilocybin could offer new avenues for mental health treatment, paralleling insights gained from cannabis and cannabinoid research and other drug studies involving substances such as mescaline and amphetamines.

Study at a glance

Abstract

No abstract available from the source.